Stem Cell Therapies Still Facing Commercial Challenges
July 22, 2016
A report from GBI Research states while the stem cell therapy pipeline is relatively large, with 330 products in active development across all stages, a number of obstacles remain before they become widely commercially viable.
The company's survey of key opinion leaders reveals that the stem cells field is "still surrounded by a wide variety of obstacles, most notably the high cost of research, which survey participants stated was the biggest factor limiting stem cell progress".
GBI analyst Rodrigo Gutierrez Gamboa commented: “Manufacturers will need to adopt novel strategies to realize their full potential. It is likely that manufacturing methodologies will use partially or fully automated systems in future approaches, in order to improve yield, purity and cost-effectiveness.
He added: “There have been good strides made by stem cell manufacturing companies, such as those made by Cynata Therapeutics, which is implementing innovative manufacturing methods to generate robust, consistent and inexpensive stem cells. Such companies are pointing towards a promising outlook in this regard.”
Stem Cell Therapies – Global Trends in the Competitive, Technological and R&D Landscape
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
